MedTrace Logo

Activated Charcoal Use in Chronic Kidney Disease Patients

NCT06906874 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-08

No results posted yet for this study

Summary

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Conditions

  • End Stage Renal Disease (ESRD)
  • CKD 5D, Hemodialysis
  • CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Interventions

DRUG

Activated Charcoal

oral activated charcoal capsules

DRUG

Phosphate Binders

calcium-based or non-calcium based (sevelamer) binders

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06906874 on ClinicalTrials.gov